MedPath

Elraglusib

Generic Name
Elraglusib
Drug Type
Small Molecule
Chemical Formula
C22H13FN2O5
CAS Number
1034895-42-5
Unique Ingredient Identifier
ND1SOF0DLU

Overview

Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).

Background

Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY)
Phase 1
Not yet recruiting
Posted: 2025/03/26
Sponsor:
Anwaar Saeed
ID:NCT06896188
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
Phase 2
Active, not recruiting
Posted: 2022/02/14
Sponsor:
Anwaar Saeed
ID:NCT05239182
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Phase 2
Withdrawn
Posted: 2021/11/11
Sponsor:Brown University
ID:NCT05116800
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
Phase 2
Recruiting
Posted: 2021/10/14
Sponsor:
Colin D. Weekes, M.D...
ID:NCT05077800
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Phase 2
Active, not recruiting
Posted: 2021/08/18
Sponsor:
Glenn J. Hanna
ID:NCT05010629

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy